Global Viral Vectors And Plasmid Dna Manufacturing Market By Product Type (Viral Vectors, Plasmid Dna, Non-Viral Vectors), By Disease Indication (Cancer, Inherited Disorders, Viral Infections, Other Applications), By Region And Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2019-2029

Market.us announces publication of its most recently generated research report titled, “Global Viral Vector and Plasmid DNA Manufacturing Market by Product Type (Viral Vectors, Plasmid DNA and   Non-Viral Vectors), By Disease Indication (Cancer, Inherited Disorders, Viral Infections, Other Indications), and by Region – Global Forecast to 2029”, which offers a holistic view of the global viral vector and plasmid DNA manufacturing market through systematic segmentation that covers every aspect of the target market.

The Global Viral Vector and Plasmid DNA Manufacturing Market is projected to be US$ 537 Mn in 2019 to reach US$ 2,436.2 Mn by 2028 at a CAGR of 18.3%.

The efficacy of gene therapy largely relies on the potential to safely deliver genetic information to target cells, either by the in-vivo or ex-vivo route. Ex-vivo requires the target cells to be extracted from the patient, transfected with the therapeutic gene, and returned to the patient once the gene transfer is complete. While, the in-vivo procedure requires the vector to be introduced into the host, where it transduces target cells within the whole organism. Gene transfer has been successfully achieved with the help of viral and non-viral vectors. Currently, both viral and non-viral vectors have registered robust growth in preclinical and clinical settings.

Request Covid - 19 Impact

Recent technological advancements in the research and biotechnology field are other significant factors fueling the growth of the target market. Improvements towards the development of effective design, scalable, and cost-effective production of viral vectors and plasmid DNA, as well as continuous research and late-stage clinical trials, are expected to affect the market growth positively. However, the manufacturing of viral vectors and plasmid DNA is a complex, costly, and time-consuming process. Several products in the pre-clinical and clinical phases may not get approved, which leads to a massive loss of investment, time, and efforts. This is one of the significant factor challenging growth of the target market.

Global Viral Vector and Plasmid DNA Manufacturing Market Revenue (US$ Mn), 2019–2029

Nonetheless, even though some developing economies are poor of funding, infrastructure capabilities, and technological know-how, they hold immense potential for viral vector and plasmid DNA manufacturing. Countries such as China, India, Brazil, Mexico, have a strong manufacturing background in almost every domain. R&D activities, government support and assistance from significant biotechnology companies may help the companies to set-up scalable manufacturing facilities and at low cost, thus limiting a large financial burden. This is expected to provide lucrative opportunities to the players and further boost growth of the market.

The global viral vector and plasmid DNA manufacturing market is segmented on the basis of product type, disease indication, and region. On the basis of product type, the market is segmented into viral Vectors, plasmid DNA and non-viral vectors. The viral vectors segment accounts for the majority share and is expected to register highest growth over the forecast period, followed by the plasmid DNA segment. Based on disease indication, the market is segmented into cancer, inherited disorders, viral infections, other indications. The cancer segment accounts for a majority share in the global viral vector and plasmid DNA manufacturing market.

Global Viral Vector and Plasmid DNA Manufacturing Market Attractiveness Analysis by Product Type, 2013–2019

On the basis of region, the market is segmented into North America, Europe, Asia Pacific, South America, and Middle East Africa. North America holds a significant revenue share in the global viral vector and plasmid DNA manufacturing market, owing to the growing prevalence and incidence of life-threatening diseases including infectious disease, cancer, genetic disorders, and other indications are expected to be some of the other significant factors driving growth of the target market. Europe is expected to register the highest growth rate over the forecast period. Regions such as APAC, South America, and MEA are expected to register stable growth over the forecast period.

The research report on the global viral vector and plasmid DNA manufacturing market includes profiles of some of the major companies such as Merck KGaA (Bioreliance), Lonza Group AG, Mylan NV, Gedeon Richter Plc, Thermo Fisher Scientific, Inc., Kaneka Corporation, Oxford Biomedica PLC, Finvector Oy, Fujifilm Diosynth Biotechnologies U.S.A, uniQure NV, Molecular Medicine SpA, Biovian Oy, GeneOne Life Science, Inc. (VGXI, INC.), PlasmidFactory GmbH & Co. KG.

Key Market Segments

Type

• Viral Vectors
• Plasmid Dna
• Non-Viral Vectors

Application

• Cancers
• Inherited Disorders
• Viral Infections
• Others

Key Market Players included in the report:

• Merck KGaA (Bioreliance)
• Lonza Group AG
• Mylan NV
• Gedeon Richter Plc
• Thermo Fisher Scientific Inc.
• Kaneka Corporation
• Oxford Biomedica PLC
• Finvector Oy
• Fujifilm Diosynth Biotechnologies U.S.A
• uniQure NV
• Molecular Medicine SpA
• Biovian Oy
• GeneOne Life Science Inc. (VGXI INC.)
• PlasmidFactory GmbH & Co. KG

For the Viral Vectors and Plasmid DNA Manufacturing Market research study, the following years have been considered to estimate the market size: